grant
Role of IL-33 in KRAS and STK11 mutant non-small cell lung cancer
Organization NORTHPORT VA MEDICAL CENTERLocation NORTHPORT, UNITED STATESPosted 1 Jul 2025Deadline 30 Jun 2029
VANIHUS FederalResearch GrantFY20252,4,D/2,4,5,TA549AbscissionAntioncogene Protein p53AreaArmed Forces PersonnelAsthmaB blood cellsB cellB cellsB-CellsB-LymphocytesB-cellB220Blood leukocyteBlood monocyteBronchial AsthmaC-K-RASCD4 CellsCD4 Positive T LymphocytesCD4 T cellsCD4 helper T cellCD4 lymphocyteCD4+ T-LymphocyteCD4-Positive LymphocytesCD45CD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCOPDCancer CauseCancer EtiologyCancer cell lineCancersCell BodyCell LineCell secretionCellLineCellsCellular SecretionCellular Tumor Antigen P53Cessation of lifeCheckpoint inhibitorChronic Obstruction Pulmonary DiseaseChronic Obstructive Lung DiseaseChronic Obstructive Pulmonary DiseaseClinical TrialsComputerized Medical RecordDNA AlterationDNA Sequence AlterationDNA mutationDataDeathDiseaseDisorderElectronic Medical RecordExcisionExtirpationFrequenciesGEM modelGEMM modelGP180Generalized GrowthGenetic AlterationGenetic ChangeGenetic defectGenetic mutationGenetically Engineered MouseGenomic TestingGenotypeGoalsGrowthHealth CareHumanImmuneImmune checkpoint inhibitorImmune mediated therapyImmune responseImmune systemImmunesImmunofluorescenceImmunofluorescence ImmunologicImmunologic SubtypingImmunologically Directed TherapyImmunophenotypingImmunotherapyImplantInfiltrationInflammatoryInfrastructureInterleukinsK-RAS2AK-RAS2BK-RasK-Ras 2AK-Ras-2 OncogeneK-ras mouse modelKRASKRAS driven oncogenesisKRAS oncogenesisKRAS(G12D)KRAS-driven tumorigenesisKRAS-mediated tumorigenesisKRAS2KRAS2 geneKRASG12DKi-RASKnowledgeKras mouse modelKras murine modelLKB1LKB1/STK11 GeneLY5LeftLeucocytic infiltrateLeukocytesLeukocytes Reticuloendothelial SystemLinkLungLung Respiratory SystemMacrophageMalignant NeoplasmsMalignant TumorMalignant Tumor of the LungMalignant neoplasm of lungMapsMarrow leukocyteMarrow monocyteMeasuresMediatingMedical centerMessenger RNAMiceMice MammalsMilitaryMilitary PersonnelModern ManMurineMusMutationMφNSCLCNSCLC - Non-Small Cell Lung CancerNamesNew YorkNon-Small Cell Lung CancerNon-Small-Cell Lung CarcinomaOncogene K-RasOncoprotein p53Operative ProceduresOperative Surgical ProceduresOutcomeP53PTPRCPTPRC genePathway interactionsPatternPersonsPhasePhosphoprotein P53Phosphoprotein pp53PopulationPreclinical dataPrevalenceProductionProtein TP53Pulmonary CancerPulmonary malignant NeoplasmRASK2Receptor ProteinRemovalReportingResearch SpecimenResistanceRoleSTK11STK11 geneSamplingSequence AlterationSignaling MoleculeSiteSpecimenStrains Cell LinesSurgicalSurgical InterventionsSurgical ProcedureSurgical RemovalT200T4 CellsT4 LymphocytesT8 CellsT8 LymphocytesTP53TP53 geneTRP53TestingTissue GrowthTobacco ConsumptionTobacco useTranslationsTreatment outcomeTumor BiologyTumor CellTumor Cell LineTumor PromotionTumor Protein p53Tumor Protein p53 GeneTumor TissueTumor-DerivedUnited States Department of Veterans AffairsUnited States Veterans AdministrationVeteransVeterans AdministrationVeterans AffairsWhite Blood CellsWhite CellWild Type MouseWorkagent orangeanti-cancer immunotherapyanticancer immunotherapycancer immunotherapycancer progressioncell typechronic obstructive pulmonary disordercultured cell linecytokineefficacy testingextracellulargene testinggene-based testinggenetic testinggenetically engineered mouse modelgenetically engineered murine modelgenome based testinggenome mutationgenome testinggenomic DNA testinggenomic alterationgenomic based testinggenomic clinical testinggenomic profiling testinggenomic screening testhost responseimmune check point inhibitorimmune microenvironmentimmune system responseimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based cancer therapiesimmune-based therapiesimmune-based treatmentsimmuno therapyimmunoresponseimmunosuppressive microenvironmentimmunosuppressive tumor microenvironmentimmunotherapy for cancerimmunotherapy of cancerimplantationindividualized cancer careindividualized oncologyinnovateinnovationinnovativeknowledge baseliver kinase B1loss of functionlung cancerlung cancer cellmRNAmalignancymetropolitanmilitary populationmonocytemouse modelmurine modelmutantnamenamednamingneoplasm progressionneoplasm/cancerneoplastic cellneoplastic progressionneutralizing antibodynew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapy approachesnew treatment approachnew treatment strategynovelnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapy approachoncogenic KRASoncology programontogenyp53 Antigenp53 Genesp53 Tumor Suppressorpathwaypersonalized oncologyprecision cancer careprecision cancer medicineprecision oncologypreclinical findingspreclinical informationpredict responsivenesspredicting responsepredictive biological markerpredictive biomarkerspredictive markerpredictive molecular biomarkerpreventpreventingprotein p53receptorresectionresistantresponsescRNA sequencingscRNA-seqsingle cell RNA-seqsingle cell RNAseqsingle cell expression profilingsingle cell transcriptomic profilingsingle-cell RNA sequencingsocial rolespatial relationshipsurgerytobacco product usetranslationtumortumor growthtumor immune microenvironmenttumor progressiontumor-immune system interactionsv-Ki-RAS2 Kirsten Rat Sarcoma 2 Viral Oncogene Homologwhite blood cellwhite blood corpusclewildtype mouse
Description preview
Background and innovation
Non-small cell lung cancers (NSCLC) with loss-of-function of STK11 and oncogenic KRAS
mutations are less likely to respond to anti-cancer immunotherapy. How loss of STK11 reduces
the effect of checkpoint inhibitor immunotherapy and the role of mutant KRAS in NSCLC is
poorly understood. Our preliminary pre-clinical data…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click